© 2020 MJH Life Sciences and HCPLive. All rights reserved.
August 09, 2017
Studies offer hope that CGRP antibodies will lead to better treatment for disabling headaches.
July 14, 2017
Positive 5-year efficacy and safety results shown for the interleukin-17A inhibitor.
July 10, 2017
The FDA expanded approval of a self-expanding TAVR platform to include patients who are at an intermediate risk for open-heart surgery.
The EMPA-REG OUTCOME trial shows short- and long-term benefits of empagliflozin on albuminuria in patients with T2D and CVD.